McKesson Corporation vs Zeta Global Holdings Corp — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: McKesson Corporation is far larger — about 13.1× Zeta Global Holdings Corp's market cap, and McKesson Corporation pays a 0.4% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Zeta Global Holdings Corp for 19 Days on average.
| MCK | ZETA | |
|---|---|---|
Market Cap | $108.46B | $8.29B |
Volume | 712,607 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $995.69 | $33.74 |
52-Week Low | $725.17 | $14.55 |
Typical Hold Time | 74 Days | 19 Days |
Enterprise Value | $115.00B | $8.18B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
ZETA trades at $33.09, down 1.93% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and support at $32. Fundamentally, revenue grew to $1.3B in 2025 with a gross margin of 59.48%, but net income remains negative. Recent quarters saw EPS beats, and the company is expanding internationally with a new UK hub. Analyst sentiment is positive with 12 buy ratings and a $32.40 consensus target.
The outlook is cautiously optimistic due to strong revenue growth and AI-driven customer adoption, but profitability risks persist with negative net margins and high valuation multiples. Investors should weigh growth potential against execution risks and competitive pressures in the tech services sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →